Top 8 drugs from new Merck

The Associated Press has put out a helpful list of Merck's top-selling drugs for the fourth quarter, now that it has merged with Schering-Plough. So we thought we'd take a look at the other megamerger--Pfizer and Wyeth--and Merck's list, too. The names on both lists are familiar, and you'll notice that each list includes some drugs brought in by the respective mergers. (Ver)

* Januvia/Janumet, diabetes, $760 million, up close to 43 percent;

* Remicade, rheumatoid arthritis, $635 million, up about 29 percent;

* Zetia, cholesterol, $614 million, up 10 percent;

* Vytorin, cholesterol, $577 million, up roughly 2 percent;

* Temodar, cancer treatment, $292 million, up close to 21 percent;

* Nasonex, allergies, $286 million, up about 2 percent;

* Fosamax, osteoporosis, $285 million, down 10 percent; and

* Gardasil, HPV vaccine, $277 million, down 3 percent.

Ver anterior